Flexion Therapeutics, Inc. (NASDAQ:FLXN) insider Yamo Deniz bought 1,000 shares of Flexion Therapeutics stock in a transaction dated Tuesday, September 5th. The shares were bought at an average cost of $24.20 per share, for a total transaction of $24,200.00. Following the completion of the acquisition, the insider now owns 5,000 shares in the company, valued at approximately $121,000. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Yamo Deniz also recently made the following trade(s):

  • On Friday, September 1st, Yamo Deniz bought 3,000 shares of Flexion Therapeutics stock. The shares were bought at an average cost of $24.15 per share, for a total transaction of $72,450.00.
  • On Thursday, August 31st, Yamo Deniz bought 1,375 shares of Flexion Therapeutics stock. The shares were bought at an average cost of $25.40 per share, for a total transaction of $34,925.00.

Flexion Therapeutics, Inc. (FLXN) traded up 2.16% during mid-day trading on Friday, reaching $24.12. The company had a trading volume of 732,733 shares. The stock’s market capitalization is $769.55 million. The stock has a 50 day moving average price of $23.25 and a 200-day moving average price of $22.01. Flexion Therapeutics, Inc. has a 12-month low of $15.93 and a 12-month high of $29.41.

Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). Equities analysts anticipate that Flexion Therapeutics, Inc. will post ($3.70) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/09/16/flexion-therapeutics-inc-flxn-insider-yamo-deniz-buys-1000-shares-of-stock.html.

A number of institutional investors have recently bought and sold shares of FLXN. Fiduciary Trust Co. purchased a new position in Flexion Therapeutics during the second quarter worth about $101,000. IFP Advisors Inc grew its position in Flexion Therapeutics by 24.5% during the second quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock worth $103,000 after buying an additional 1,000 shares in the last quarter. Advisor Group Inc. grew its position in Flexion Therapeutics by 205.9% during the second quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock worth $105,000 after buying an additional 3,500 shares in the last quarter. Voya Investment Management LLC grew its position in Flexion Therapeutics by 25.8% during the second quarter. Voya Investment Management LLC now owns 12,914 shares of the specialty pharmaceutical company’s stock worth $261,000 after buying an additional 2,651 shares in the last quarter. Finally, BB&T Securities LLC purchased a new position in Flexion Therapeutics during the second quarter worth about $289,000. Institutional investors and hedge funds own 82.75% of the company’s stock.

Several research firms have recently issued reports on FLXN. BMO Capital Markets reissued a “buy” rating on shares of Flexion Therapeutics in a report on Friday, August 11th. Needham & Company LLC reissued a “buy” rating and set a $36.00 target price (up from $34.00) on shares of Flexion Therapeutics in a report on Thursday, August 10th. Zacks Investment Research raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, August 28th. Cantor Fitzgerald set a $40.00 target price on Flexion Therapeutics and gave the stock a “buy” rating in a report on Monday, June 12th. Finally, Janney Montgomery Scott reissued a “buy” rating and set a $35.00 target price (up from $30.00) on shares of Flexion Therapeutics in a report on Wednesday, July 12th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $31.50.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Insider Buying and Selling by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Stock Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related stocks with our FREE daily email newsletter.